vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving Average of $16.01

vTv Therapeutics Inc. (NASDAQ:VTVT)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $16.01 and traded as low as $13.21. vTv Therapeutics shares last traded at $13.21, with a volume of 6,966 shares changing hands.

vTv Therapeutics Stock Performance

The stock has a market capitalization of $39.76 million, a price-to-earnings ratio of -1.49 and a beta of 0.65. The business’s 50 day simple moving average is $16.01 and its 200-day simple moving average is $20.43.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in vTv Therapeutics stock. Baker BROS. Advisors LP bought a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned 3.23% of vTv Therapeutics at the end of the most recent reporting period. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.